Progress and prognosis in juvenile dermatomyositis

Jeffrey A. Dvergsten, Ann M. Reed

Research output: Contribution to journalReview articlepeer-review


With the advent of corticosteroids as a treatment option for autoimmune disease in the early 1960s, the course of juvenile dermatomyositis was altered from one of high mortality to one with various degrees of morbidity. Prior to treatment with corticosteroids, juvenile dermatomyositis resulted in recovery, recovery with chronic disability or death. Corticosteroids significantly decreased mortality and by modifying disease course, morbidity but introduced additional complications. Biomarkers of disease activity, as well as predictors of disease course and severity, are lacking but are a focus of current investigation. Improved understanding of pathogenesis has expanded medication choices to treat both new-onset and refractory disease. Published consensus treatment plans are being implemented, facilitating studies of comparative effectiveness and toxicity.

Original languageEnglish (US)
Pages (from-to)567-584
Number of pages18
JournalInternational Journal of Clinical Rheumatology
Issue number6
StatePublished - Dec 1 2014


  • biomarkers
  • consensus treatment plans
  • corticosteroids
  • morbidity
  • mortality
  • pathogenesis
  • refractory disease

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Progress and prognosis in juvenile dermatomyositis'. Together they form a unique fingerprint.

Cite this